# AstraZeneca: Phase 3 study in Gastric, Esophagogastric Junction (140 participants)

**Score:** 75/100

| Field | Value |
|---|---|
| Sponsor | AstraZeneca |
| Sponsor type | Industry (pharma, biotech, medtech) |
| Study | A Study of Neoadjuvant-adjuvant Durvalumab and FLOT Chemotherapy Followed by Adjuvant Durvalumab in Chinese Patients With Resectable GC/GEJC. |
| NCT ID | NCT07877818 |
| Phase | Phase 3 |
| Status | not yet recruiting |
| Conditions | Gastric; Esophagogastric Junction |
| Intervention types | drug |
| Target enrollment | 140 |
| Posted | 2026-10-16 |
| Planned start | 2026-11-30 |
| Event | Newly registered study |
| Event date | 2026-10-16 |

## Why this score
- Industry sponsor (buys outsourced services).
- Phase 3: multi-site, larger budget.
- 140 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07877818). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.